A Phase 1 interventional study of Levodopa and Carbidopa in Healthy Volunteers, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Germany. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-27.
Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase I PK study in healthy males.
This is a phase I, open, repeated dose, randomised PK study in healthy males. The study will consist of 4 parallel groups (Groups 1-4). All groups will have a crossover design with 4 treatment periods, each lasting for 7 days.
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
At the screening visit:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
levodopa 50 mg, carbidopa 12.5 mg
Drug: Levodopa · Drug: Carbidopa
levodopa 50 mg, carbidopa 65 mg
Drug: Levodopa · Drug: Carbidopa
levodopa 50 mg, carbidopa 65 mg, ODM-104 50 mg
Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104
levodopa 50 mg, carbidopa 65 mg, ODM-104 100 mg A4 ; B4 l; C4 ; D4 levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg
Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104
levodopa 100 mg, carbidopa 25 mg
Drug: Levodopa · Drug: Carbidopa
levodopa 100 mg, carbidopa 65 mg
Drug: Levodopa · Drug: Carbidopa
levodopa 100 mg, carbidopa 65 mg, ODM-104 50 mg
Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104
levodopa 100 mg, carbidopa 37,5 mg
Drug: Levodopa · Drug: Carbidopa
levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg
Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104
levodopa 150 mg, carbidopa 65 mg
Drug: Levodopa · Drug: Carbidopa
levodopa 150 mg, carbidopa 65 mg, ODM-104 50 mg
Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104
levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg
Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104
levodopa IR 100 mg (Sinemet), carbidopa 25 mg
Drug: Levodopa · Drug: Carbidopa
levodopa 100 mg, carbidopa 65 mg
Drug: Levodopa · Drug: Carbidopa
levodopa 100 mg, carbidopa 25 mg, ODM-104 100 mg
Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104
levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg
Drug: Levodopa · Drug: Carbidopa · Drug: ODM-104
Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24)
Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24)
Time frame: During 24 hours
Fluctuation of Levodopa Cmax/Cmin, Tau
Explore fluctuation of levodopa Cmax/Cmin, tau. Figures given are per performed statistical analysis.
Time frame: 16 hours
Levodopa Peak Plasma Concentration (Cmax)
Levodopa peak plasma concentration (Cmax)
Time frame: 24 hours
| Milestone | Group 1 | Group 2 | Group 3 | Group 4 |
|---|---|---|---|---|
| Started | 14 | 14 | 14 | 14 |
| Completed | 12 | 13 | 12 | 13 |
| Not completed | 2 | 1 | 2 | 1 |
| Withdrew: Adverse event | 0 | 1 | 1 | 1 |
| Withdrew: Personal reason | 2 | 0 | 1 | 0 |
Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24)
| h*ng/ml | A1 50 mg LD + 12.5 mg CD | B1 50 mg LD + 65 mg CD | C1 50 mg LD + 65 mg CD + 50 mg ODM-104 | D1 50 mg LD + 65 mg CD + 100 mg ODM-104 | A2 100 mg LD + 25 mg CD | B2 100 mg LD + 65 mg CD | C2 100 mg of LD + 65 mg CD + 50 mg ODM-104 | D2 100 mg LD + 65 mg CD + 100 mg of ODM-104 | A3 150 mg LD + 37.5 mg CD | B3 150 mg LD + 65 mg CD | C3 150 mg LD + 65 mg CD + 50 mg ODM-104 | D3 150 mg LD + 65 mg CD + 100 mg ODM-104 | A4 (Sinemet) 100 mg IR LD + 25 mg CD | B4 100 mg LD + 65 mg CD | C4 100 mg LD + 25 mg CD + 100 mg ODM-104 | D4 100 mg LD + 65 mg CD + 100 mg ODM-104 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24) | 4300 (3905 to 4734) | 5423 (4928 to 5968) | 7439 (6760 to 8186) | 9046 (8215 to 9960) | 9643 (9060 to 10263) | 10709 (10062 to 11399) | 15257 (14335 to 16239) | 17896 (16814 to 19048) | 14285 (13550 to 15061) | 15805 (14995 to 16658) | 22473 (21316 to 23693) | 25672 (24390 to 27021) | 7965 (6436 to 9859) | 8994 (7286 to 11104) | 13866 (11232 to 17118) | 16310 (13140 to 20246) |
Explore fluctuation of levodopa Cmax/Cmin, tau. Figures given are per performed statistical analysis.
| (ng/ml)/(ng/ml) | A1 50 mg LD + 12.5 mg CD | B1 50 mg LD + 65 mg CD | C1 50 mg LD + 65 mg CD + 50 mg ODM-104 | D1 50 mg LD + 65 mg CD + 100 mg ODM-104 | A2 100 mg LD + 25 mg CD | B2 100 mg LD + 65 mg CD | C2 100 mg of LD + 65 mg CD + 50 mg ODM-104 | D2 100 mg LD + 65 mg CD + 100 mg of ODM-104 | A3 150 mg LD + 37.5 mg CD | B3 150 mg LD + 65 mg CD | C3 150 mg LD + 65 mg CD + 50 mg ODM-104 | D3 150 mg LD + 65 mg CD + 100 mg ODM-104 | A4 (Sinemet) 100 mg IR LD + 25 mg CD | B4 100 mg LD + 65 mg CD | C4 100 mg LD + 25 mg CD + 100 mg ODM-104 | D4 100 mg LD + 65 mg CD + 100 mg ODM-104 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fluctuation of Levodopa Cmax/Cmin, Tau | 12.24 ± 5.73 | 7.49 ± 2.23 | 4.16 ± 0.77 | 3.02 ± 1.00 | 11.00 ± 3.30 | 8.32 ± 2.23 | 4.46 ± 1.09 | 3.35 ± 0.74 | 8.45 ± 3.16 | 7.16 ± 3.87 | 3.67 ± 1.29 | 2.82 ± 0.99 | 19.52 ± 14.13 | 9.18 ± 6.23 | 7.63 ± 12.96 | 3.04 ± 0.76 |
Levodopa peak plasma concentration (Cmax)
| ng/ml | A1 50 mg LD + 12.5 mg CD | B1 50 mg LD + 65 mg CD | C1 50 mg LD + 65 mg CD + 50 mg ODM-104 | D1 50 mg LD + 65 mg CD + 100 mg ODM-104 | A2 100 mg LD + 25 mg CD | B2 100 mg LD + 65 mg CD | C2 100 mg of LD + 65 mg CD + 50 mg ODM-104 | D2 100 mg LD + 65 mg CD + 100 mg of ODM-104 | A3 150 mg LD + 37.5 mg CD | B3 150 mg LD + 65 mg CD | C3 150 mg LD + 65 mg CD + 50 mg ODM-104 | D3 150 mg LD + 65 mg CD + 100 mg ODM-104 | A4 (Sinemet) 100 mg IR LD + 25 mg CD | B4 100 mg LD + 65 mg CD | C4 100 mg LD + 25 mg CD + 100 mg ODM-104 | D4 100 mg LD + 65 mg CD + 100 mg ODM-104 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Levodopa Peak Plasma Concentration (Cmax) | 685.92 ± 193.08 | 775.36 ± 186.29 | 908.86 ± 230.23 | 950.38 ± 241.60 | 1519.92 ± 294.51 | 1593.85 ± 288.95 | 1855.38 ± 240.58 | 1955.38 ± 278.62 | 2105.45 ± 422.05 | 2072.73 ± 403.78 | 2545.45 ± 424.30 | 2616.67 ± 388.76 | 1634.62 ± 361.70 | 1367.36 ± 352.26 | 1711.43 ± 316.10 | 1717.69 ± 641.60 |
Collected over Through study completion, upto 15 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A1 (Levodopa 50, Carbidopa 12.5) | 0/14 (0%) | 0/14 (0%) | 6/14 (42.9%) |
| B1 (Levodopa 50, Carbidopa 65) | 0/14 (0%) | 0/14 (0%) | 8/14 (57.1%) |
| C1 (Levodopa 50, Carbidopa 65, ODM-104 50) | 0/14 (0%) | 0/14 (0%) | 7/14 (50%) |
| D1 (Levodopa 50, Carbidopa 65, ODM-104 100) | 0/14 (0%) | 0/14 (0%) | 7/14 (50%) |
| A2 (levodopa100, Carbidopa 25) | 0/14 (0%) | 0/14 (0%) | 6/14 (42.9%) |
| B2 (Levodopa 100, Carbidopa 65) | 0/14 (0%) | 2/14 (14.3%) | 7/14 (50%) |
| C2 (levodopa100, Carbidopa 65, ODM-104 50) | 0/14 (0%) | 0/14 (0%) | 8/14 (57.1%) |
| D2 (Levodopa 100, Carbidopa 65, ODM-104 100) | 0/14 (0%) | 0/14 (0%) | 7/14 (50%) |
| A3 (Levodopa 150, Carbidopa 37.5) | 0/14 (0%) | 0/14 (0%) | 7/14 (50%) |
| B3 (Levodopa 150, Carbidopa 65) | 0/14 (0%) | 0/14 (0%) | 4/14 (28.6%) |
| C3 (Levodopa 150, Carbidopa 65, ODM-104 50) | 0/14 (0%) | 0/14 (0%) | 9/14 (64.3%) |
| D3 (Levodopa 150, Carbidopa 65, ODM-104 100) | 0/14 (0%) | 0/14 (0%) | 10/14 (71.4%) |
| A4 (Sinemet, Levodopa 100, Carbidopa 25) | 0/14 (0%) | 0/14 (0%) | 6/14 (42.9%) |
| B4 (Levodopa 100, Carbidopa 65) | 0/14 (0%) | 0/14 (0%) | 5/14 (35.7%) |
| C4 (Levodopa 100, Carbidopa 25, ODM-104 100) | 0/14 (0%) | 0/14 (0%) | 5/14 (35.7%) |
| D4 (Levodopa 100, Carbidopa 65, ODM-104 100) | 0/14 (0%) | 0/14 (0%) | 9/14 (64.3%) |
| Event | A1 (Levodopa 50, Carbidopa 12.5) | B1 (Levodopa 50, Carbidopa 65) | C1 (Levodopa 50, Carbidopa 65, ODM-104 50) | D1 (Levodopa 50, Carbidopa 65, ODM-104 100) | A2 (levodopa100, Carbidopa 25) | B2 (Levodopa 100, Carbidopa 65) | C2 (levodopa100, Carbidopa 65, ODM-104 50) | D2 (Levodopa 100, Carbidopa 65, ODM-104 100) | A3 (Levodopa 150, Carbidopa 37.5) | B3 (Levodopa 150, Carbidopa 65) | C3 (Levodopa 150, Carbidopa 65, ODM-104 50) | D3 (Levodopa 150, Carbidopa 65, ODM-104 100) | A4 (Sinemet, Levodopa 100, Carbidopa 25) | B4 (Levodopa 100, Carbidopa 65) | C4 (Levodopa 100, Carbidopa 25, ODM-104 100) | D4 (Levodopa 100, Carbidopa 65, ODM-104 100) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiverticulitisReproductive system and breast disorders | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 1/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 |
| PeritonitisReproductive system and breast disorders | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 1/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 |
| Event | A1 (Levodopa 50, Carbidopa 12.5) | B1 (Levodopa 50, Carbidopa 65) | C1 (Levodopa 50, Carbidopa 65, ODM-104 50) | D1 (Levodopa 50, Carbidopa 65, ODM-104 100) | A2 (levodopa100, Carbidopa 25) | B2 (Levodopa 100, Carbidopa 65) | C2 (levodopa100, Carbidopa 65, ODM-104 50) | D2 (Levodopa 100, Carbidopa 65, ODM-104 100) | A3 (Levodopa 150, Carbidopa 37.5) | B3 (Levodopa 150, Carbidopa 65) | C3 (Levodopa 150, Carbidopa 65, ODM-104 50) | D3 (Levodopa 150, Carbidopa 65, ODM-104 100) | A4 (Sinemet, Levodopa 100, Carbidopa 25) | B4 (Levodopa 100, Carbidopa 65) | C4 (Levodopa 100, Carbidopa 25, ODM-104 100) | D4 (Levodopa 100, Carbidopa 65, ODM-104 100) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/14 | 3/14 | 3/14 | 0/14 | 5/14 | 1/14 | 0/14 | 4/14 | 4/14 | 0/14 | 1/14 | 3/14 | 1/14 | 4/14 | 1/14 | 3/14 |
| FatigueGeneral disorders | 1/14 | 5/14 | 0/14 | 0/14 | 1/14 | 1/14 | 2/14 | 2/14 | 0/14 | 0/14 | 0/14 | 1/14 | 0/14 | 0/14 | 1/14 | 0/14 |
| DizzinessNervous system disorders | 3/14 | 1/14 | 0/14 | 1/14 | 0/14 | 2/14 | 1/14 | 1/14 | 0/14 | 0/14 | 1/14 | 0/14 | 2/14 | 0/14 | 0/14 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 3/14 | 2/14 | 1/14 | 0/14 | 0/14 | 2/14 | 0/14 | 1/14 | 1/14 | 0/14 | 0/14 | 2/14 | 0/14 | 0/14 | 2/14 | 0/14 |
| NauseaGastrointestinal disorders | 0/14 | 0/14 | 0/14 | 3/14 | 0/14 | 1/14 | 0/14 | 1/14 | 1/14 | 2/14 | 2/14 | 2/14 | 1/14 | 0/14 | 2/14 | 1/14 |
| RhinitisInfections and infestations | 0/14 | 3/14 | 0/14 | 0/14 | 0/14 | 0/14 | 1/14 | 2/14 | 0/14 | 0/14 | 0/14 | 0/14 | 2/14 | 1/14 | 0/14 | 2/14 |
| Abdominal painGastrointestinal disorders | 1/14 | 3/14 | 1/14 | 0/14 | 0/14 | 0/14 | 0/14 | 2/14 | 0/14 | 0/14 | 0/14 | 1/14 | 0/14 | 0/14 | 1/14 | 0/14 |
| Abdominal pain lowerGastrointestinal disorders | 1/14 | 0/14 | 0/14 | 0/14 | 0/14 | 1/14 | 0/14 | 2/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 |
| FlatulenceGastrointestinal disorders | 1/14 | 0/14 | 1/14 | 0/14 | 0/14 | 0/14 | 2/14 | 2/14 | 2/14 | 1/14 | 2/14 | 2/14 | 1/14 | 1/14 | 1/14 | 1/14 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/14 | 0/14 | 0/14 | 0/14 | 2/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 2/14 | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 |
| Age, Categorical(Participants) | Group 1 | Group 2 | Group 3 | Group 4 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 14 | 14 | 14 | 14 | 56 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Group 1 | Group 2 | Group 3 | Group 4 | Total |
|---|---|---|---|---|---|
| Mean | 42.4 ± 13.7 | 49.5 ± 10.9 | 48.0 ± 13.5 | 46.0 ± 10.6 | 46.4 ± 12.2 |
| Sex: Female, Male(Participants) | Group 1 | Group 2 | Group 3 | Group 4 | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 14 | 14 | 14 | 14 | 56 |
| Sex: Female, Male(Participants) | Group 1 | Group 2 | Group 3 | Group 4 | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 14 | 14 | 14 | 14 | 56 |
| Race (NIH/OMB)(Participants) | Group 1 | Group 2 | Group 3 | Group 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 1 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 13 | 13 | 13 | 13 | 52 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Group 1 | Group 2 | Group 3 | Group 4 | Total |
|---|---|---|---|---|---|
| Germany | 14 | 14 | 14 | 14 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in Jun 2017, 3 months.
Results were first posted in May 2021, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Levodopa · Carbidopa
Orion Corporation, Orion Pharma →